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Background. Keratoconus has classically been deﬁned as a noninﬂammatory disorder, although recent studies show elevated levels
of inﬂammatory markers suggesting that keratoconus could be, at least in part, an inﬂammatory condition. Heparanase
upregulation has been described in multiple inﬂammatory disorders. In this article, we study the diﬀerential expression of
heparanase in cornea and tears from keratoconus patients and healthy controls. Methods. A transcriptomic approach was used
employing quantitative polymerase chain reaction to analyze the expression of heparanase and heparanase 2 in stromal and
epithelial corneal cells. The protein expression was analyzed by immunohistochemistry in corneal sections. Enzymatic activity in
tears was measured using [3H]-labeled heparan sulfate as substrate. Results. Heparanase transcription was detected in stromal
and epithelial cells and appeared upregulated in keratoconus. Overexpression of the enzyme was also detected by
immunohistochemistry. Corneal expression of heparanase 2 was detected in some cases. Heparanase catalytic activity was found
in tears and displayed a positive correlation with the degree of keratoconus. Conclusions. Heparanase overexpresses in
keratoconic corneas, possibly reinforcing the inﬂammatory condition of the pathology. The presence of heparanase activity in
tears allows us to propose its use as a biomarker for the diagnosis of the disorder.
1. Introduction
Keratoconus is a corneal ectasia that results in the cornea tak-
ing on a conical shape, causing severe astigmatism, scarring,
and, for one in ﬁve patients, ultimately loss of vision and the
need for corneal transplants [1].
Histologically, keratoconus displays many abnormal
features which aﬀect diﬀerent layers of the cornea, including
abnormal epithelial and stromal keratocyte shape, local
thickening of the epithelium, Bowman’s layer breakage, and
thinning of the stroma [2, 3]. Keratoconus is likely a multi-
factorial, multigenetic disorder with complex inheritance
patterns, and environmental factors probably play an equally
important role in disease causation [4]. Although keratoco-
nus has traditionally been viewed as a noninﬂammatory dis-
ease, reports of the presence of certain inﬂammatory
mediators in keratoconus patients has led some authors to
suggest that inﬂammation plays a role in the onset or pro-
gression of the pathology [5].
Proteoglycans (PGs) are a diverse group of glycoconju-
gates composed of various core proteins posttranslationally
modiﬁed with linear, anionic polysaccharides called glycos-
aminoglycans (GAGs), consisting of repeating disaccharides.
Heparan sulfate proteoglycans (HSPGs) comprise a reduced
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and speciﬁc group of proteins covalently linked to heparan
sulfate (HS) GAG chains. HS is a complex biopolymer ini-
tially created as a chain of alternating D-glucuronic acid
and N-acetylated-D-glucosamine. At various positions, the
molecule is modiﬁed by a series of interdependent enzy-
matic reactions that include N-deacetylation of N-acety-
lated-D-glucosamine, usually followed by N-sulfation,
epimerization of D-glucuronic acid into iduronate, and the
addition of sulfate groups at C2 of uronic acid, and at C6
and C3 of glucosamine residues [6]. Chain modiﬁcation
results in clusters of highly sulfated and iduronate-rich
regions separated by more ﬂexible low or nonsulfated
regions [7]. Speciﬁc sets of variably modiﬁed disaccharides,
usually within the sulfated domains, can deﬁne binding sites
for a multitude of speciﬁc ligands, including cytokines, che-
mokines, growth factors, enzymes and enzyme inhibitors,
and extracellular matrix (ECM) proteins [6]. A variety of
normal and pathological functions have been ascribed to
HSPGs, including cell adhesion and migration, organization
of the ECM, regulation of proliferation, diﬀerentiation and
morphogenesis, cytoskeleton organization, tissue repair,
inﬂammation, vascularization, and cancer metastasis [6, 8].
All corneal cells express HSPGs, which are ubiquitously
present in tissues and are mainly associated with the cell
surface and the ECM [6, 8]. Various eye diseases appear
related to changes in PGs and GAGs, although there are
few studies examining alterations in these molecules in con-
nection with keratoconus [9–12]. Recently, however, there
have been reports of changes in corneal stromal cells in ker-
atoconus that point to an increase in HS chains and their
levels of sulfation [13].
Heparanase (HPSE) is an endo-β-D-glucuronidase that
cleaves speciﬁc linkages in the structure of the HS, yielding
fragments which are able to contain biological activity. With
a few exceptions, in normal noncancerous cells, the HPSE
gene is not transcribed [14], although its expression has been
reported in murine corneal epithelium and several retinal
layers [15]. HPSE expression is induced in all major types
of human cancer, is often associated with reduced patient
survival and increased tumor metastasis [16], and has been
shown to be associated with numerous inﬂammatory condi-
tions, such as inﬂammatory bowel disease and rheumatoid
arthritis [14]. Increased corneal expression of this molecule
has also been reported during infection, most likely due to
HPSE-positive inﬁltrating cells. [15]. Heparanase 2 (HPSE2)
is a homologue of HPSE that lacks HS-degrading activity,
although it is able to interact with HS with high aﬃnity
[16]. HPSE2 is capable of associating with HPSE, thereby
possibly modulating its enzymatic activity and signaling
properties [16, 17].
In this paper, we investigate the expression patterns of
heparanase genes in the keratoconus cornea in comparison
to healthy controls. The study analyzes both the transcription
and the protein levels in the corneal tissues using qRT-PCR
and immunohistochemistry. Taking into account that the
tear proteome displays a highly dynamic character, we inves-
tigated the levels of heparanase enzymatic activity in tears of
keratoconus patients of diﬀerent grades in an eﬀort to deﬁne
its use as a biomarker for this eye disorder.
2. Methods
2.1. Materials. The following materials were purchased from
the manufacturers indicated: RNeasy Kit and RNase-Free
DNase from Qiagen (Hilden, Germany); High-Capacity
cDNA Reverse Transcription Kit and Power SYBR Green
PCR Master Mix from Applied Biosystems (Foster City,
CA); GenElute PCR clean-up kit, 3-3′-diaminobenzidine,
heparinase I and III blend from Flavobacterium heparinum,
and heparan sulfate from Sigma-Aldrich (St. Louis, MO);
EnVision™ Flex/HRP and Envision FLEX target retrieval
solution of high pH from Dako (Glostrup, Denmark);
cellulose acetate ﬁlter paper with pore size of 0.22μm was
purchased from Sartorius Stedim (Göttingen, Germany); tet-
racaine hydrochloride and oxibuprocain hydrochloride were
from Alcon Cusí (Barcelona, Spain); DMEM+F12 culture
medium containing nonessential amino acids, RPMI 1640
Vitamin Solution 100x, 1% antibiotics (penicillin/streptomy-
cin), and fetal bovine serum from Gibco (Waltham, MA);
HiTrap Desalting column, superose 12, and [3H]acetic anhy-
dride (500mCi/mmol) from GE Healthcare Life Sciences
(Little Chalfont, UK); Vivaspin 500 centrifugal ﬁlter units
from Sartorius (Gotinga, Germany). All other chemicals
were obtained from commercial sources and were of ana-
lytical grade.
The following antibodies were used in this study: goat
anti-heparanase 1 polyclonal antibody (L-19) and rabbit
polyclonal anti-heparanase 1 (H-80), both purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and rabbit
anti-heparanase-2 polyclonal antibody, purchased from
Thermo Fischer Scientiﬁc (Waltham, MA). Anti-rabbit (sc-
2004) and anti-goat (sc-2005) secondary antibodies were also
from Santa Cruz Biotechnology (Santa Cruz, CA).
2.2. Isolation and Culture of Corneal Stromal Cells. Human
central corneal tissue was obtained from cadaver donors
and from penetrating keratoplasty interventions on
patients suﬀering from keratoconus. Healthy donor tissues
were screened and tested negative for HIV, hepatitis B and
C virus, and syphilis and were not usable for human cor-
neal transplantation.
The epithelium was removed with ethanol (70%, 30 s)
and a spatula, and the endothelium by Descemet membrane
endothelial keratoplasty, after which the absence of epithelial
and endothelial cells was assessed by microscopy. Corneal
stromal cells were obtained by digesting 2mm diameter
pieces from the central cornea in 0.25% trypsin/ethylenedi-
aminetetraacetic acid solution for 30min at 37°C. After
centrifugation, the supernatant was discarded and the pellet
resuspended in a DMEM+F12 culture medium containing
nonessential amino acids, RPMI 1640 Vitamin Solution
100x, 1% antibiotics (penicillin/streptomycin), and 10% fetal
bovine serum. When cultures reached 80% conﬂuence, they
were replated at a density of 2× 105 cells/ml in 75 cm2 poly-
styrene ﬂasks and incubated at 37°C in a 5% (v/v) CO2 atmo-
sphere. As a control to evaluate whether cells maintained a
stable phenotype, we performed alpha-smooth muscle actin
immunostaining; this staining remained negative at least
until the ﬁfth passage, suggesting that the stromal cells did
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not readily diﬀerentiate to myoﬁbroblasts. As a result, only
cultures in passages 1–5 were used. In all studies carried out
in this work, the diﬀerent cell lines were analyzed separately.
2.3. Obtaining Corneal Epithelial Samples by Impression
Cytology.All the samplesused in this studywereobtained from
patients (n = 8) from the Instituto Oftalmológico Fernández-
Vega (IOFV, Asturias, Spain) and from healthy volunteers
(n = 5). Informed oral and written consent of the patients
and volunteers was obtained under a protocol approved by
the Ethical Committee of the IOFV in accordance with the
guidelines of the Tenets of the Declaration of Helsinki.
Prior to impression, one drop of local anaesthetic (0.1%
tetracaine hydrochloride and 0.4% oxibuprocain hydrochlo-
ride) was instilled into the eye and excessive tear ﬂuid and
medication were wiped away. Next, a 6mm disc of cellulose
acetate paper was applied gently onto the corneal surface
with the aid of sterile blunt forceps. The paper was allowed
to remain in contact with the central cornea for 5 seconds,
peeled oﬀ, turned over, and the other side applied for an
additional period of 5 seconds. The paper was immediately
transferred into RNase-free tubes and rapidly frozen and
stored at −80°C.
2.4. Obtaining Tear Fluid Samples. Tear ﬂuid was obtained
from patients (n = 42) and healthy volunteers (n = 11) with
the same range of ages by using a sterile capilar tube and
applying gentle suction with a syringe. The ﬂuid was imme-
diately transferred into sterile tubes containing 20% of the
ﬁnal volume in glycerol and rapidly frozen and stored at
−80°C. A minimum of 10μl of tear ﬂuid was required to be
included as a valid sample.
2.5. RNA Isolation and cDNA Synthesis. Tissue fragments (20
and 30mg in weight) were homogenized using a polytron PT
2100 (Kinematica Inc.; Bohemia, NY), and RNA was isolated
using the RNeasy kit (Qiagen, Hilden, Germany) and proc-
essed as previously described [18]. To ensure removal of
residual contaminating DNA, samples were subjected to
treatment with RNase-free DNase during the puriﬁcation
process itself. The concentration of RNA obtained was deter-
mined spectrophotometrically by measuring absorbance at
260nm of a 1 : 50 dilution using a BioPhotometer (Eppen-
dorf; Hamburg, Germany). cDNA synthesis was carried out
using the High Capacity cDNA Transcription Kit (Applied
Biosystems, Foster City, CA, USA). The reactions were per-
formed using a thermocycler iCycler IQ (BioRad; Hercules,
CA), using 2μg of RNA as starting material. The reaction
products were cleaned using the PCR Clean-Up GenElute
Kit in line with the manufacturer’s instructions. Finally, the
aliquots containing the cDNA were diluted 1 : 20 with water
and used for qRT-PCR assays or stored at −20°C until use.
2.6. Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR) and Data Analysis. The primer sequences were
HPSE (gene ID 10855) forward 5′-ATGCTCAGTTGCTC
CTGGAC-3′, reverse 5′-CTCCTAACTGCGACCCATTG-3′
and HPSE2 (gene ID 60495) forward 5′-CACCCTGATGT
TATGCTGGAG-3′, reverse 5′-TCCAGAGCAATCAGCA
AAGTTA-3′. qRT-PCR reactions, and analysis of amplimer
products were carried out accordingly to the methods already
detailed [19]. Actin was included on each plate as a control
gene to compare run variation and to normalize individual
gene expression. Statistical analysis of the data and expres-
sion of the values of diﬀerential transcription were performed
as previously described [18].
2.7. Immunohistochemistry. Tissue sections from the central
cornea, prepared as previously described [13], were dewaxed,
and the rehydrated sections were rinsed in phosphate-
buﬀered saline containing 1% Tween-20, and then immuno-
stained as previously described [13].
2.8. Radioisotopic Labeling and Molecular Size Fractionation
of HS. HS was partially de-N-acetylated and re-N-acetylated
with [3H]acetic anhydride according to the method previ-
ously described [20]. Molecular size fractionation of HS was
carried out using size-exclusion chromatography. 20μCi of
[3H]-HS was applied to a superose 12 column connected to
an FPLC system (GE) and eluted with 50mM of pH8.0
Tris-HCl buﬀer and 150mM of NaCl at a ﬂow rate of 1ml/
min. 1ml fractions were collected, and HS eluting from the
column was determined by measuring the radioactivity in
200μl aliquots of each fraction. Fractions including mole-
cules of high molecular weight were pooled and precipitated
with 85% ethanol for 2 h at −80°C. The identity of the poly-
saccharide was conﬁrmed by exclusion chromatography in
the same conditions after treatment with a mixture of hepar-
inases I and III.
2.9. Heparanase Assay. The ability of the tears to fragment
HS chains was monitored by ultraﬁltration. The reactions
were carried out in a total volume of 200μl that included
100mM citrate buﬀer pH5.3, 1mM CaCl2, 20 nCi of [
3H]-
HS and 10μl of tears. The reactions were incubated for 16h
at 37°C and stopped by the addition of 220μl of 2M NaCl
and 200μl of chloroform. After vigorous shaking, the sample
was centrifuged at 10,000×g and 200μl of the aqueous
phase was extracted. 100μl of extract was ultraﬁltered using
ﬁlters with an exclusion size of 5 kDa which had previously
been treated with 500ml of 20% glycerol. Filtration was car-
ried out at 12,000×g for 5 minutes, and the reaction was
measured by determining the radioactivity in aliquots of
the ﬁltrate.
2.10. Statistical Analysis.All analyses were performed using the
Statistics for Windows program (Statsoft Inc.; Tulsa, OK).
Mean values were compared between two samples by the
Mann–Whitney U test and between multiple samples by the
Kruskal–Wallis test. Correlations were assessed by Pearson’s
correlation coeﬃcient. p < 0 05 was accepted as signiﬁcant.
3. Results
Analysis of the diﬀerential transcription of the genes encod-
ing heparanases in keratoconic corneas was carried out by
qRT-PCR. The study was conducted independently for cor-
neal stroma (using cultures of diﬀerent stromal cells lines
obtained from diﬀerent healthy corneas and keratoconic
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patients) and for epithelium (using samples obtained by
impression cytology). In healthy cornea, HPSE transcripts
could be detected both in the stromal and in the epithelial
cells, although levels were about two orders of magnitude
higher in the latter. Keratoconic cornea also displayed HPSE
transcripts in both types of tissue, although it is worth noting
that it was overexpressed, about 6- to 7-fold, compared to the
respective values observed in healthy individuals (Figure 1),
diﬀerences which were statistically signiﬁcant (p < 0 001).
HPSE2 transcripts were also detected, mainly in epithelial
cells, although not in all the individuals analyzed, and the
values found in healthy tissue did not display signiﬁcant dif-
ferences from keratoconic cornea (Figure 1).
HPSE is synthesized as a proenzyme of 61.2 kDa, which is
cleaved by cathepsin L to generate the active form consisting
of 8 and 50 kDa subunits that associate noncovalently [16].
We evaluated changes in the expression of the HPSE protein
by immunohistochemistry using two diﬀerent antibodies. L-
19 antibody recognizes peptide mapping near the C-
terminus of the molecule and is consequently present in both
the catalytically active form and in the latent precursor.
Using this antibody on healthy corneas resulted in certain
levels of staining, predominantly in the basal layers of the
epithelium (Figure 2, A). In contrast, the corneas of keratoco-
nus patients showed signiﬁcant increases in staining, both in
the epithelium and in the stroma; at the level of the epithe-
lium, a homogeneous overexpression in keratoconus was
observed, while the stroma showed a particularly intense
overexpression, predominantly in the subepithelial region
(Figure 2, B). H-80 antibody is produced against amino acids
101–180 so that it is able to recognize only the inactive pre-
cursor. Immunohistochemical analysis of corneas using this
antibody resulted in faint stainings, mainly detectable in ker-
atoconic epithelia (Figure 2, C and D). Furthermore, immu-
nostaining of corneas with anti-heparanase 2 antibodies
allowed the detection of certain levels of expression, espe-
cially in the epithelium, suggesting the presence of the pro-
tein in these corneas (Figure 2, E and F).
The presence of endo-β-D-glucuronidase activity in tears
was tested for by determining the appearance of ultraﬁlter-
able HS fragments of low molecular weight resulting from
the hydrolysis of high molecular weight [3H]-labeled HS.
The results showed that low levels of HPSE activity could
be detected in tears of healthy individuals and that in kerato-
conic individuals the level progressively increased as the
Rabinowitz grade of the keratoconus increased (Figure 3).
Diﬀerences between tears from keratoconic and healthy
individuals were statistically signiﬁcant in all the cases, as
they were between the diﬀerent grades except for between
grades 1 and 2. This case, though, approached signiﬁcance
(p = 0 07), suggesting that it may well be positive if a wider
sample of patients were used. The data showed a strong pos-
itive correlation between HPSE activity and the grade of the
keratoconus (r = 0 89, p < 0 001).
4. Discussion
HSPGs are present in all types of human cells, albeit that HS
species from diﬀerent sources diﬀer in terms of molecular
size and their overall patterns of chain modiﬁcation. Based
on their structural diversity, HS chains are able to selec-
tively interact with many diﬀerent types of soluble and
insoluble proteins, lipids, and even microorganisms, thereby
modulating numerous cellular activities, including cell
adhesion and migration, organization of the ECM, regula-
tion of proliferation, diﬀerentiation and morphogenesis,
cytoskeleton organization, tissue repair, inﬂammation, vas-
cularization, and cancer metastasis [6, 8]. Given the impor-
tance of the biological functions in which it participates, the
enzymatic remodeling of HSPGs profoundly aﬀects a wide
variety of physiological and pathological processes [14,
16]. HPSE is the sole human endoglycosidase that cleaves
HS, although this molecule also displays various nonenzy-
matic activities [16, 17].
Whereas HS is produced by virtually all cells in the body,
HPSE expression is kept tightly regulated at the transcrip-
tional and posttranslational levels, since any uncontrolled
cleavage of HS could result in signiﬁcant tissue damage [14,
16]. HPSE expression in noncancerous cells has been
reported to be restricted to certain speciﬁc cases, such as in
the placenta, activated immune cells, and keratinocytes
[21]. With respect to its expression in ocular tissues, studies
in murine eyes have reported constitutive expression in the
corneal epithelium and several retinal layers [15]. In this
article, we report the expression of certain levels of HPSE in
healthy corneas, predominantly in the basal layers of the
epithelium. It is of note that corneas of keratoconus patients
signiﬁcantly overexpressed HPSE at both the epithelial and
stromal level. Upregulation of HPSE associated with patho-
logical processes has been widely described, including
tumors, inﬂammatory bowel disease, rheumatoid arthritis,
diabetic nephropathy, or atherosclerosis [14, 16, 22].
Increased levels of HPSE have also been related to ocular
pathologies, such as the overexpression in corneal epithelium
and stroma during infection with Pseudomonas aeruginosa
10−4
10−3
10−2
10−1
1
(a) (b)
Ep
ith
eli
um
Ep
ith
eli
um
St
ro
m
a
St
ro
m
a
Re
la
tiv
e t
ra
ns
cr
ip
t a
bu
nd
an
ce
⁎
⁎
Figure 1: Diﬀerential transcription of genes encoding heparanases.
Relative abundance for healthy cells (black bars) and keratoconic
cells (gray bars) are plotted for HPSE (a) and HPSE2 (b). Values
on the y-axis are on a logarithmic scale. ∗p < 0 001; error bars,
standard deviations.
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[15] and in the vitreous of patients with proliferative diabetic
retinopathy [23].
The upregulation of HPSE in cornea associated with
Pseudomonas infection has been related to HPSE-positive
inﬁltrating cells, and it was not able to be detected in corneas
from immunized mice since they had a lower inﬂammatory
response [15]. However, in our study, we were able to detect
an approximately 6- to 7-fold increase in the transcription of
the gene using epithelial cells, obtained by impression cytol-
ogy, and cultured stromal cells, clearly suggesting that the
observed overexpression occurs as a result of increased tran-
scription in the corneal cells themselves. The protein is ﬁrst
synthesized as a latent 65 kDa proenzyme that is secreted
via vesicles that bud from the Golgi apparatus, which then
interacts with cell membrane HSPGs and other receptors,
accumulates in endosomes, and undergoes processing at
two proteolytic cleavage sites, located at Glu109-Ser110 and
Gln157-Lys158, yielding 8- and 50-kDa subunits that hetero-
dimerize to form the active enzyme. Using an antibody (H80)
that recognizes an internal region present only in the 65 kDa
form of the protein, we were able to detect immunostaining
in epithelial cells, particularly in keratoconic epithelial cells.
These immunostainings showed faint labeling, as would be
expected for a molecular species that is temporary, in con-
trast to the intense labeling obtained for the ﬁnal, processed
HPSE. Together, these results indicate that the transcrip-
tional and posttranslational regulation of the expression of
the molecule occurs in the corneal cells.
HPSE upregulation, locally expressed at the site of
inﬂammation, has been shown in multiple organ systems as
well as in several autoimmune and human autoinﬂammatory
disorders, although its precise mode of action is not
completely understood [14]. The enzymatic degradation of
HS aﬀects several aspects of inﬂammatory response, includ-
ing the release of cytokines and chemokines, the activation
of immune cells, and leukocyte recruitment [14]. Keratoco-
nus has traditionally been deﬁned as a noninﬂammatory
disorder due to the lack of neovascularization and cellular
inﬁltration [24]. However, recent studies have shown the
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Figure 2: Immunohistochemistry of heparanases. (A–D) Immunohistochemistry of HPSE carried out using the antibody L-19 (A, B) and the
antibody H-80 (C, D). (E, F) Immunohistochemistry of HPSE2. The column on the left shows the results obtained using healthy corneal
sections, and that on the right the results using keratoconic corneal sections.
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signiﬁcant role of proteolytic enzymes, cytokines, and free
radicals. Moreover, evidence increasingly supports the
notion that thinning and ectasia of the cornea are related to
a degraded extracellular matrix involving inﬂammatory
events, which include increased levels of matrix metallopro-
teinases [24] and which might be reinforced by the action
of HPSE. It has also been described that loss of corneal epi-
thelial sulfate leads to corneal degeneration [25], and the
health of the ocular surface involves soluble factors whose
action may be strongly inﬂuenced by HPSE, as in the case
of lacritin [26]. Some authors have proposed that the deﬁni-
tion of inﬂammation should not necessarily be limited to the
absence of neovascularization and lack of marked cellular
inﬁltration [25]. Taking this line, the upregulation of HPSE
in keratoconus could be added to the elevated levels of other
inﬂammatory markers to suggest that keratoconus could be,
at least in part, an inﬂammatory condition.
HPSE2 is a homologue of HPSE that lacks HS-degrading
activity, although it is able to interact with HS with high aﬃn-
ity and is capable of modulating HPSE enzymatic activity and
signaling properties, such that an antimetastatic character
has been proposed for it [16]. Although it has previously been
suggested that this molecule is not expressed in the eye [27],
in the current work, it was indeed possible to detect
transcripts in epithelial cells, although not in all the cases
analyzed. Immunohistochemistry also detected certain levels
of protein, although no signiﬁcant diﬀerences were found
between normal and keratoconic cells.
Mature HPSE is located in lysosomes, which are not
considered typical secretory vesicles. Nevertheless, they
may secrete their content in response to local or systemic
cues, which releases the enzymatically active molecule and
other molecules like cathepsins into the extracellular milieu
[16, 28]. It has been reported that HPSE secretion increases
in response to proinﬂammatory cytokines such as TNFα,
although the eﬀective stimuli vary among cell types and
biological settings [28]. Altered levels of inﬂammatory cyto-
kines, including TNFα, have been reported in tears of kera-
toconic patients, as well as elevated levels of cathepsins [5,
29]. Using [3H]-labeled HS, we were able to detect the pres-
ence of certain low levels of HPSE catalytic activity in tears
from healthy individuals. This activity greatly increased in
tears of keratoconic patients, and the values showed a strong
positive correlation with the grade of keratoconus. The tear
proteome displays a highly dynamic character that may
reﬂect the altered states of speciﬁc eye disorders, as has been
described in meibonian gland disease [30], autoimmune thy-
roid eye disease [31], pterygium [32], ocular rosacea [33],
blepharitis [34], diabetes [35], and dry eye [36]. In the case
of keratoconus, previous reports have shown diﬀerences in
the tear protein proﬁle [37], although the changes found
do not include HPSE, probably because the methodology
used does not directly detect the protein, but rather its cata-
lytic activity, which allows higher sensitivity.
5. Conclusions
In summary, this work describes an overexpression of HPSE
in keratoconic corneas that aﬀects both the epithelium and
the stroma. The presence of catalytic activity in tears is also
reported, and this activity shows a positive correlation with
the grade of keratoconus, thus allowing its use as a biomarker
for the diagnosis of the disorder.
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